Peptides / CJC-1295 / United Kingdom

CJC-1295 in the United Kingdom

Legal status, what it is, and the listed suppliers in the United Kingdom that list it.

Legal status in the United Kingdom

Not an approved medicine.

As understood at 2026-09-22. Verify with the MHRA.

What CJC-1295 is

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), modified so that it binds to the body's own albumin after injection and lasts far longer than the natural hormone, with a half-life of about eight days. Several listed suppliers also sell a product labelled 'CJC-1295 no DAC', which lacks that modification; it is a different molecule from the one in the trials below.

Full CJC-1295 page: targets and research →

Clinical Research

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA (2006). Journal of Clinical Endocrinology & Metabolism. human healthy adults, phase I, two small dose-ranging studies
Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog
Ionescu M, Frohman LA (2006). The Journal of Clinical Endocrinology & Metabolism. human healthy men aged 20 to 40, blood sampled every 20 minutes over a 12-hour overnight period before and a week after a single injection